The reasons for those patients inability to control the EBV infection are still unknown. However no effective treatment is currently available, those patients might benefit from early HSCT. Through this study, we hope to identify the unknown immune immunodeficiencies and pathophysiology of those EBV-associated conditions. The investigators propose to help make early diagnosis and develop effective therapies.